Archive
API

National Coverage Determination (NCD)

Microvolt T-Wave Alternans (MTWA)

20.30

Expand All | Collapse All

Tracking Information

Publication Number
100-3
Manual Section Number
20.30
Manual Section Title
Microvolt T-Wave Alternans (MTWA)
Version Number
1
Effective Date of this Version
03/21/2006
Ending Effective Date of this Version
05/12/2008
Implementation Date
04/03/2006
Implementation QR Modifier Date

Description Information

Benefit Category
Diagnostic Tests (other)


Please Note: This may not be an exhaustive list of all applicable Medicare benefit categories for this item or service.

Item/Service Description

A.     General

Microvolt T-wave Alternans(MTWA) testing is a non-invasive diagnostic test that detects minute electrical activity in a portion of the electrocardiogram(EKG) know as the T-wave.  MTWA testing has a role in the risk stratification of patients who may be at risk for sudden cardiac death(SCD) from ventricular arrhythmias.

Within patient groups that may be considered candidates for implantable cardioverter defibrillator(ICD) therapy, a negative MTWA test may be useful in identifying low-risk patients who are unlikely to benefit from, and who may experience worse outcomes from ICD placement.

The test is performed by placing highly sensitive electrodes on a patient's chest prior to a period of controlled exercise.  These electrodes detect tiny beat-to-beat changes, on the order of one-millionth of volt, in the EKG T-wave.  Spectral analysis is used to calculate these minute voltage changes.  Spectral analysis is a sensitive mathematical method of measuring and comparing time and the EKG signals.  Software then analyzes these microvolt changes and produces a report to be interpreted by a physician.
Indications and Limitations of Coverage

B.     Nationally Covered Indications

Microvolt T-wave Alternans diagnostic testing is covered for the evaluation of patients at risk for SCD, only when the spectral analysis method is used.

C.     Nationally Non-Covered Indications

Microvolt T-wave Alternans diagnostic test is non-covered for the evaluation of patients at risk for SCD if measurement is not performed employing the spectral analysis.

D.     Other

N/A

 

(This NCD last reviewed March 2006)
Cross Reference
Claims Processing Instructions

Transmittal Information

Transmittal Number
49
Coverage Transmittal Link
https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/Downloads/R49NCD.pdf
Revision History

03/2006 - Effective Date: 03/21/2006. Implementation Date: 04/03/2006. (TN 49) CR4351
Other

National Coverage Analyses (NCAs)

This NCD has been or is currently being reviewed under the National Coverage Determination process. The following are existing associations with NCAs, from the National Coverage Analyses database.

Coding Analyses for Labs (CALs)

This NCD has been or is currently being reviewed under the National Coverage Determination process. The following are existing associations with CALs, from the Coding Analyses for Labs database.

Additional Information

Other Versions
Title Version Effective Between
Microvolt T-Wave Alternans (MTWA) 3 01/13/2015 - N/A View
Microvolt T-Wave Alternans (MTWA) 2 05/12/2008 - 01/13/2015 View
Microvolt T-Wave Alternans (MTWA) 1 03/21/2006 - 05/12/2008 You are here
CPT Copyright Statement
CPT only copyright 2002-2011 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
Reasons for Denial
Note: This section has not been negotiated by the Negotiated RuleMaking Committee. It includes CMS’s interpretation of it’s longstanding policies and is included for informational purposes. Tests for screening purposes that are performed in the absense of signs, symptoms, complaints, or personal history of disease or injury are not covered except as explicity authorized by statue. These include exams required by insurance companies, business establishments, government agencies, or other third parties. Tests that are not reasonable and necessary for the diagnosis or treatment of an illness or injury are not covered according to the statue. Failure to provide documentation of the medical necessity of tests may result in denial of claims. The documentation may include notes documenting relevant signs, symptoms, or abnormal findings that substantiate the medical necessity for ordering the tests. In addition, failure to provide independent verification that the test was ordered by the treating physician (or qualified nonphysician practitioner) through documentation in the physician’s office may result in denial. A claim for a test for which there is a national coverage or local medical review policy will be denied as not reasonable and necessary if it is submitted without an ICD-9-CM code or narrative diagnosis listed as covered in the policy unless other medical documentation justifying the necessity is submitted with the claim. If a national or local policy identifies a frequency expectation, a claim for a test that exceeds that expectation may be denied as not reasonable and necessary, unless it is submitted with documentation justifying increased frequency. Tests that are not ordered by a treating physician or other qualified treating nonphysician practitioner acting within the scope of their license and in compliance with Medicare requirements will be denied as not reasonable and necessary. Failure of the laboratory performing the test to have the appropriate Clinical Laboratory Improvement Act of 1988 (CLIA) certificate for the testing performed will result in denial of claims.
Submit Feedback/Ask a Question